A Retrospective Investigation of 28 Cats with Intermediate- to Large-Cell Lymphoma Treated with Lomustine and Prednisolone as a First-Line Chemotherapy.
Clinical evidence update from Animals : an open access journal from MDPI
Clinical Context
Peer-reviewed veterinary literature continues to shape everyday decision-making for feline patients, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.
What the Study Evaluated
A study published in Animals : an open access journal from MDPI in 2026 evaluated a Retrospective Investigation of 28 Cats with Intermediate- to Large-Cell Lymphoma Treated with Lomustine and Prednisolone as a First-Line Chemotherapy..
Key Findings
Lymphoma is the most common neoplastic disease in cats; however, lomustine has been insufficiently evaluated as a first-line chemotherapeutic agent. This study assessed treatment response, survival, and progression-free interval (PFI) in cats with intermediate-to-large cell lymphoma treated with lomustine and prednisolone as first-line therapy. Twenty-eight cats with cytologically or histopathologically confirmed lymphoma received lomustine (10 mg/cat every 3 weeks) and prednisolone until disease progression or unacceptable toxicity. All cats were feline leukemia virus- and feline immunodeficiency virus-negative, with a mean age of 9.93...
Why It Matters for Veterinary Professionals
For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for feline patients.
Practical Interpretation
The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.
Clinical Takeaway
Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.
Read the full article here.
Comments
Related Articles
Copyright © 2026 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment